Hawthorne Health Strengthens Leadership and Board of Directors

In January, Hawthorne Health, a leader in technology-enabled mobile clinical research, announced the appointment of Josh Rose as new CEO. Josh is a clinical trial industry veteran with over 14 years of executive leadership experience with blue chip companies such as IQVIA, CVS Health and others. Rose's expertise combines market strategy, M&A, new business growth and operations, and track record of commercial success, is perfectly matched to further accelerate Hawthorne Health growth.

I've always been attracted to companies that have a unique approach to solving significant industry challenges. Driving greater patient access and participation in clinical trials is one of the most pressing challenges for pharma sponsors. Hawthorne Health's pioneering approach to rapidly enabling study visits in the patient's home at attractive unit economics, eliminates the barrier for greater adoption of mobile visits in hybrid or any clinical trial.

Josh Rose, CEO, Hawthorne Health

Hawthorne Health has also strengthened its board of directors with three new appointments who together bring over 50 years of clinical trials, biotechnology and patient services experience. New directors include Jon DiVincenzo, EVP & President, Central Laboratories Services and International, Labcorp, Tony Clapsis, former SVP at CVS Health, and Ingo Chakravarty, operating partner at Northpond Ventures and former CEO of Mesa (sold to Fisher Scientific). New members join current board members Jodi Akin (Hawthorne Health founder) and Lucy Coassin.

Transforming clinical trials is not about flashy tech and buzz words. It's brass-tacks operational delivery with practical solutions that work. With the industry's largest network of GCP trained independent clinicians, enabled by a novel tech approach, Hawthorne Health rapidly matches and schedules mobile trial visits anywhere.

Tony Clapsis, Board Member

Labcorp and Hawthorne Health recently announced a strategic partnership to increase patient diversity, decrease site burden, and accelerate enrollment and clinical study timelines.

At Labcorp, we are committed to making life-saving clinical trials more accessible, diverse and inclusive to all communities. Through this collaboration, we look forward to combining Labcorp's global laboratory network and logistics capabilities with Hawthorne Health's digital platform to advance our decentralized clinical trial capabilities, increase clinical trial accessibility and diversity, and bring greater value to patients, their physicians and our sponsors.

Jon DiVincenzo, Labcorp